Global Colon Cancer Association shared a post on LinkedIn:
“New Op-Ed in the Washington Examiner from Andrew Spiegel, Esq.
As CEO of the Global Colon Cancer Association, Andrew has spent decades fighting to ensure patients get the right medicine at the right time. Today, he’s sounding the alarm on a drug pricing policy that could put that mission at risk.
In his op-ed, Andrew explains why the Trump administration’s proposed “Most Favored Nation” (MFN) drug pricing policy could harm cancer patients here and around the world.
By tying U.S. drug prices to artificially low foreign prices, MFN risks:
- Cutting pharmaceutical R&D spending dramatically, potentially meaning hundreds fewer new medicines over the next decade
- Importing the same access barriers that leave patients in Japan accessing only 43% of new medicines, and patients across 19 high-income countries accessing just 36%
- Hurting cancer patients who depend on continuous innovation for lifesaving treatment
The goal of making drugs more affordable is right. The mechanism matters enormously. Andrew outlines a smarter path forward, one that pressures wealthy nations to pay their fair share without sacrificing American patients or innovation.”
Read the full op-ed in the Washington Examiner
Other articles about Global Colon Cancer Association on OncoDaily.